Clinical pharmacology of bispecific antibody constructs

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S21-S28

  Rathi, Chetan ^a   Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

antibody; bispecific; diabody; pharmacokinetics

Indexed keywords

BISPECIFIC ANTIBODY; BLINATUMOMAB; CATUMAXOMAB; ANTINEOPLASTIC AGENT;

ARTICLE; BEHAVIOR; CLINICAL PHARMACOLOGY; DEVELOPMENTAL STAGE; HUMAN; IMMUNOGENICITY; NONHUMAN; ONCOLOGY; PROTEIN ENGINEERING; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; EYE DISEASES; NEOPLASMS;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; EYE DISEASES; HUMANS; NEOPLASMS;

EID: 84923363809     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.445     Document Type: Article

References (64)

1. Meibohm B,. Protein engineering for improved pharmacologic characteristics of established monoclonal antibody-based therapeutics. Clin Pharmacokinet. 2014; 53 (10): 863-864.
2. Aggarwal RS,. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol. 2014; 32 (1): 32-39.
3. Carter PJ,. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res. 2011; 317 (9): 1261-1269.
4. Chan AC, Carter PJ,. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev Immunol. 2010; 10 (5): 301-316.
5. Reichert JM,. Monoclonal antibodies as innovative therapeutics. Curr Pharmaceut Biotechnol. 2008; 9 (6): 423-430.
6. Thurber GM, Schmidt MM, Wittrup KD,. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008; 29 (2): 57-61.
7. Chirmule N, Jawa V, Meibohm B,. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012; 14 (2): 296-302.
8. Wu AM, Senter PD,. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005; 23 (9): 1137-1146.
9. Kontermann RE,. Dual targeting strategies with bispecific antibodies. mAbs. 2012; 4 (2): 182-197.
10. May C, Sapra P, Gerber HP,. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol. 2012; 84 (9): 1105-1112.
11. Hollander N,. Bispecific antibodies for cancer therapy. Immunotherapy. 2009; 1 (2): 211-222.
12. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ,. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 2013; 31 (11): 621-632.
13. Ott MG, Marme F, Moldenhauer G, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer. 2012; 130 (9): 2195-2203.
14. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010; 127 (9): 2209-2221.
15. Jin P, Zhu Z,. The Design and Engineering of IgG-Like Bispecific Antibodies. In Bispecific Antibodies. Berlin: Springer; 2011: 151-169.
16. Wu C, Ying H, Grinnell C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007; 25 (11): 1290-1297.
17. Lameris R, de Bruin RC, Schneiders FL, et al. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol/Hematol. 2014; 92 (3): 153-165.
18. Portell CA, Wenzell CM, Advani AS,. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 2013; 5 (Suppl 1): 5-11.
19. Baum V, Buhler P, Gierschner D, et al. Antitumor activities of PSMAxCD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013; 5 (1): 27-38.
20. Kontermann RE,. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin. 2005; 26 (1): 1-9.
21. Borchmann P, Schnell R, Fuss I, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002; 100 (9): 3101-3107.
22. Meibohm B,. Pharmacokinetics and pharmacodynamics of peptide and protein therapeutics. In:, Crommelin DJA, Sindelar RB, Meibohm B, eds. Pharmaceutical Biotechnology: Fundamentals and Applications. 4th ed. New York: Springer; 2013: 101-132.
23. Tang L, Persky AM, Hochhaus G, Meibohm B,. Pharmacokinetic aspects of biotechnology products. J Pharmaceut Sci. 2004; 93 (9): 2184-2204.
24. Meibohm B,. Pharmacokinetics and half-life of protein therapeutics. In:, Kontermann RE, ed. Therapeutic Proteins: Strategies to Modulate their Plasma Half-Lives. Weinheim: Wiley-VCH; 2012: 23-38.
25. Rippe B, Haraldsson B,. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994; 74 (1): 163-219.
26. Labrijn AF, Meesters JI, de Goeij BE, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA. 2013; 110 (13): 5145-5150.
27. Chames P, Van Regenmortel M, Weiss E, Baty D,. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009; 157 (2): 220-233.
28. Fujimori K, Covell DG, Fletcher JE, Weinstein JN,. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med. 1990; 31 (7): 1191-1198.
29. Holliger P, Hudson PJ,. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005; 23 (9): 1126-1136.
30. List T, Neri D,. Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. mAbs. 2012; 4 (6): 775-783.
31. Tang L, Meibohm B,. Pharmacokinetics of peptides and proteins. In:, Meibohm B, ed. Pharmacokinetics and Pharmacodynamics of Biotech Drugs. Weinheim: Wiley-VCH; 2006: 17-43.
32. Tabrizi MA, Tseng CM, Roskos LK,. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11 (1-2): 81-88.
33. Mager DE,. Target-mediated drug disposition dynamics. Biochem Pharmacol. 2006; 72 (1): 1-10.
34. Roopenian DC, Akilesh S,. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7 (9): 715-725.
35. Diao L, Meibohm B,. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013; 52 (10): 855-868.
36. Dirks NL, Meibohm B,. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49 (10): 633-659.
37. Yamane-Ohnuki N, Satoh M,. Production of therapeutic antibodies with controlled fucosylation. mAbs. 2009; 1 (3): 230-236.
38. Yip V, Palma E, Tesar DB, et al. Quantitative cumulative biodistribution of antibodies in mice: Effect of modulating binding affinity to the neonatal Fc receptor. mAbs. 2014; 6 (3): 689-696.
39. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA,. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010; 21 (12): 2153-2163.
40. Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PloS One. 2013; 8 (2): e57479.
41. Meibohm B, Zhou H,. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012; 52 (1 Suppl): 54S-62S.
42. McDonagh CF, Huhalov A, Harms BD, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Therap. 2012; 11 (3): 582-593.
43. Stork R, Campigna E, Robert B, Muller D, Kontermann RE,. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem. 2009; 284 (38): 25612-25619.
44. Stork R, Zettlitz KA, Muller D, Rether M, Hanisch FG, Kontermann RE,. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem. 2008; 283 (12): 7804-7812.
45. Buhler P, Wolf P, Gierschner D, et al. A bispecific diabody directed against prostate-specific membrane antigen,CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol. 2008; 57 (1): 43-52.
46. Seimetz D, Lindhofer H, Bokemeyer C,. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treatment Rev. 2010; 36 (6): 458-467.
47. Ruf P, Kluge M, Jager M, et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol. 2010; 69 (6): 617-625.
48. Ober RJ, Radu CG, Ghetie V, Ward ES,. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001; 13 (12): 1551-1559.
49. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29 (18): 2493-2498.
50. Viardot A, Goebeler M, Pfreundschuh M, et al. Open-label phase 2 study of the bispecific T-cell engager (BiTE®) blinatumomab in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2013; 122 (21): 1811.
51. Amgen Inc. Background information for the pediatric subcommittee of the oncologic drugs advisory committee meeting-04 October 2012. US Food and Drug Administration. 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM330210.pdf
52. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012; 119 (26): 6226-6233.
53. Nagorsen D, Kufer P, Baeuerle PA, Bargou R,. Blinatumomab: a historical perspective. Pharmacol Therap. 2012; 136 (3): 334-342.
54. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321 (5891): 974-977.
55. Wurster U, Haas J,. Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol. 1994; 57: 21-25.
56. Atwal JK, Chen Y, Chiu C, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med. 2011; 3 (84): 84ra43.
57. Kissel K, Hamm S, Schulz M, Vecchi A, Garlanda C, Engelhardt B,. Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochem Cell Biol. 1998; 110 (1): 63-72.
58. Jones AR, Shusta EV,. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharmaceut Res. 2007; 24 (9): 1759-1771.
59. Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE,. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res. 1987; 18 (2): 299-304.
60. Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011; 3 (84): 84ra44.
61. Mabry R, Gilbertson DG, Frank A, et al. A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. mAbs. 2010; 2 (1): 20-34.
62. Le Couter J, Scheer JM,. Bispecific therapeutics for ophthalmic indications: target selection and the optimal molecular format. Exp Rev Ophthalmol. 2014; 9 (3): 217-225.
63. Duerr H, Herting F, Klein C, Regula JT, Rueth M, Stubenrauch KG,. CNY Patent application: Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases. Vol US20140017244 A1: US Patent and Trademark Office. 2014.
64. Beck A, Wurch T, Bailly C, Corvaia N,. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010; 10 (5): 345-352.